One CD4+TCR and one CD8+TCR targeting autochthonous neoantigens are essential and sufficient for tumor eradication.

Steven P Wolf Vasiliki Anastasopoulou Kimberley Drousch Markus I Diehl Boris Engels Poh Yin Yew Kazuma Kiyotani Yusuke Nakamura Karin Schreiber Hans Schreiber Matthias Leisegang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Two cancer-specific TCRs can be essential and sufficient to eradicate heterogeneous solid tumors expressing unmanipulated, autochthonous targets. We demonstrate that simplifications to adoptive TCR-therapy are possible without compromising efficacy.

Keyphrases

regulatory t cells
papillary thyroid
cell therapy
nk cells
helicobacter pylori infection
cancer therapy
stem cells
squamous cell carcinoma
young adults
drug delivery
mesenchymal stem cells
helicobacter pylori
smoking cessation